/Investor DB

Nina Capital — 2022 Investments

4 investments dated 2022 · listed companies and verified rows first · show all

Meda Systemsmedasystems.cominPre-Seed · Mar 2022 · $2M✓ verified

MedaSystems builds a software platform that automates workflows, collects real-world data, and connects physicians with pharmaceutical manufacturers to manage drugs under pre-approval and expanded-access pathways.

Digital HealthHealthtechMedical DevicesSaaSSilicon Valley, US

Brian Irwin(Chief Executive Officer)inJeffrey Thibeault(Chief Technology Officer)in

Co-investorsDebiopharm Innovation Fund

Leuko Labsleuko.cominSep 2022 · $5M

Leuko develops a noninvasive white blood cell monitor to track neutropenia risk in cancer patients and others undergoing treatment.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBoston, US

Ian Butterworth(Chief Technology Officer)inAurelien Bourquard(Chief Data Scientist)inAlvaro Sanchez-Ferro(Chief Medical Officer)inCarlos Castro-Gonzalez(Founder)inPaul Hartung(Director)in

BoardAmy Salzhauer(Director)in

Co-investorsGood Growth CapitalDorm RoomMassVenturesIAG Capital Partners

Segmedsegmed.aiin𝕏Seed · Oct 2022 · $5.2M

Segmed provides structured, de-identified medical imaging data and multimodal datasets from diverse populations to support research in AI and healthcare.

AI & Machine LearningData & InfrastructureDigital HealthHealthtechMedical DevicesSan Francisco, US

Martin Willemink(Founder)inJie Wu(Founder)inMarinus Johannes Willemink(Executive Officer, Director)Wojciech Adam Koszek(Executive Officer, Director)Cailin Hardell(Founder)Cailin Kramer(Founder)in

Co-investorsBlumberg CapitalExpeditionsiGan PartnersMighty CapitalNovaCapitalSouth Quad+4 more

Zetta Genomicszettagenomics.comin𝕏Seed · Feb 2022 · $3M

Zetta Genomics develops XetaBase, a genomic-native data management platform that loads, aggregates, indexes, annotates and queries large-scale genomic data for research and clinical use.

BiotechData & InfrastructureHealthtech

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.